128 related articles for article (PubMed ID: 37743037)
1. Vedolizumab, Adalimumab, and Methotrexate Combination Therapy in Crohn's Disease (EXPLORER).
Colombel JF; Ungaro RC; Sands BE; Siegel CA; Wolf DC; Valentine JF; Feagan BG; Neustifter B; Kadali H; Nazarey P; James A; Jairath V; Qasim Khan RM
Clin Gastroenterol Hepatol; 2024 Jul; 22(7):1487-1496.e12. PubMed ID: 37743037
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease.
Yang E; Panaccione N; Whitmire N; Dulai PS; Vande Casteele N; Singh S; Boland BS; Collins A; Sandborn WJ; Panaccione R; Battat R
Aliment Pharmacol Ther; 2020 Jun; 51(11):1031-1038. PubMed ID: 32329532
[TBL] [Abstract][Full Text] [Related]
3. Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's Disease.
Danese S; Sandborn WJ; Colombel JF; Vermeire S; Glover SC; Rimola J; Siegelman J; Jones S; Bornstein JD; Feagan BG
Gastroenterology; 2019 Oct; 157(4):1007-1018.e7. PubMed ID: 31279871
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.
Singh S; Murad MH; Fumery M; Sedano R; Jairath V; Panaccione R; Sandborn WJ; Ma C
Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1002-1014. PubMed ID: 34688373
[TBL] [Abstract][Full Text] [Related]
5. Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn's Disease.
Löwenberg M; Vermeire S; Mostafavi N; Hoentjen F; Franchimont D; Bossuyt P; Hindryckx P; Rispens T; de Vries A; van der Woude CJ; Berends S; Ambarus CA; Mathot R; Clasquin E; Baert F; D'Haens G
Gastroenterology; 2019 Oct; 157(4):997-1006.e6. PubMed ID: 31175865
[TBL] [Abstract][Full Text] [Related]
6. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
Colombel JF; Panaccione R; Bossuyt P; Lukas M; Baert F; Vaňásek T; Danalioglu A; Novacek G; Armuzzi A; Hébuterne X; Travis S; Danese S; Reinisch W; Sandborn WJ; Rutgeerts P; Hommes D; Schreiber S; Neimark E; Huang B; Zhou Q; Mendez P; Petersson J; Wallace K; Robinson AM; Thakkar RB; D'Haens G
Lancet; 2017 Dec; 390(10114):2779-2789. PubMed ID: 29096949
[TBL] [Abstract][Full Text] [Related]
7. Adalimumab for maintenance of remission in Crohn's disease.
Townsend CM; Nguyen TM; Cepek J; Abbass M; Parker CE; MacDonald JK; Khanna R; Jairath V; Feagan BG
Cochrane Database Syst Rev; 2020 May; 5(5):CD012877. PubMed ID: 32413933
[TBL] [Abstract][Full Text] [Related]
8. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study.
Kennedy NA; Heap GA; Green HD; Hamilton B; Bewshea C; Walker GJ; Thomas A; Nice R; Perry MH; Bouri S; Chanchlani N; Heerasing NM; Hendy P; Lin S; Gaya DR; Cummings JRF; Selinger CP; Lees CW; Hart AL; Parkes M; Sebastian S; Mansfield JC; Irving PM; Lindsay J; Russell RK; McDonald TJ; McGovern D; Goodhand JR; Ahmad T;
Lancet Gastroenterol Hepatol; 2019 May; 4(5):341-353. PubMed ID: 30824404
[TBL] [Abstract][Full Text] [Related]
9. Adalimumab for induction of remission in Crohn's disease.
Abbass M; Cepek J; Parker CE; Nguyen TM; MacDonald JK; Feagan BG; Khanna R; Jairath V
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31742665
[TBL] [Abstract][Full Text] [Related]
10. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC.
Ferrante M; Colombel JF; Sandborn WJ; Reinisch W; Mantzaris GJ; Kornbluth A; Rachmilewitz D; Lichtiger S; D'Haens GR; van der Woude CJ; Danese S; Diamond RH; Oortwijn AF; Tang KL; Miller M; Cornillie F; Rutgeerts PJ;
Gastroenterology; 2013 Nov; 145(5):978-986.e5. PubMed ID: 23954314
[TBL] [Abstract][Full Text] [Related]
11. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI).
Dewint P; Hansen BE; Verhey E; Oldenburg B; Hommes DW; Pierik M; Ponsioen CI; van Dullemen HM; Russel M; van Bodegraven AA; van der Woude CJ
Gut; 2014 Feb; 63(2):292-9. PubMed ID: 23525574
[TBL] [Abstract][Full Text] [Related]
12. Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease.
Bohm M; Xu R; Zhang Y; Varma S; Fischer M; Kochhar G; Boland B; Singh S; Hirten R; Ungaro R; Shmidt E; Lasch K; Jairaith V; Hudesman D; Chang S; Lukin D; Swaminath A; Sands BE; Colombel JF; Kane S; Loftus EV; Shen B; Siegel CA; Sandborn WJ; Dulai PS;
Aliment Pharmacol Ther; 2020 Aug; 52(4):669-681. PubMed ID: 32656800
[TBL] [Abstract][Full Text] [Related]
13. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.
Sands BE; Feagan BG; Rutgeerts P; Colombel JF; Sandborn WJ; Sy R; D'Haens G; Ben-Horin S; Xu J; Rosario M; Fox I; Parikh A; Milch C; Hanauer S
Gastroenterology; 2014 Sep; 147(3):618-627.e3. PubMed ID: 24859203
[TBL] [Abstract][Full Text] [Related]
14. Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease.
Christensen B; Gibson PR; Micic D; Colman RJ; Goeppinger SR; Kassim O; Yarur A; Weber CR; Cohen RD; Rubin DT
Clin Gastroenterol Hepatol; 2019 Feb; 17(3):486-493. PubMed ID: 29751166
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial.
Hanauer S; Liedert B; Balser S; Brockstedt E; Moschetti V; Schreiber S
Lancet Gastroenterol Hepatol; 2021 Oct; 6(10):816-825. PubMed ID: 34388360
[TBL] [Abstract][Full Text] [Related]
16. Vedolizumab as induction and maintenance therapy for Crohn's disease.
Sandborn WJ; Feagan BG; Rutgeerts P; Hanauer S; Colombel JF; Sands BE; Lukas M; Fedorak RN; Lee S; Bressler B; Fox I; Rosario M; Sankoh S; Xu J; Stephens K; Milch C; Parikh A;
N Engl J Med; 2013 Aug; 369(8):711-21. PubMed ID: 23964933
[TBL] [Abstract][Full Text] [Related]
17. Vedolizumab in Combination With Corticosteroids for Induction Therapy in Crohn's Disease: A Post Hoc Analysis of GEMINI 2 and 3.
Sands BE; Van Assche G; Tudor D; Akhundova-Unadkat G; Curtis RI; Tan T
Inflamm Bowel Dis; 2019 Jul; 25(8):1375-1382. PubMed ID: 30615117
[TBL] [Abstract][Full Text] [Related]
18. Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease.
Rosario M; French JL; Dirks NL; Sankoh S; Parikh A; Yang H; Danese S; Colombel JF; Smyth M; Sandborn WJ; Feagan BG; Reinisch W; Sands BE; Sans M; Fox I
J Crohns Colitis; 2017 Aug; 11(8):921-929. PubMed ID: 28333288
[TBL] [Abstract][Full Text] [Related]
19. Translating Results from VARSITY to Real World: Adalimumab vs Vedolizumab as First-line Biological in Moderate to Severe IBD.
Moens A; Verstockt B; Alsoud D; Sabino J; Ferrante M; Vermeire S
Inflamm Bowel Dis; 2022 Aug; 28(8):1135-1142. PubMed ID: 34751766
[TBL] [Abstract][Full Text] [Related]
20. Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy.
Sands BE; Sandborn WJ; Van Assche G; Lukas M; Xu J; James A; Abhyankar B; Lasch K
Inflamm Bowel Dis; 2017 Jan; 23(1):97-106. PubMed ID: 27930408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
